Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
1.
Langenbecks Arch Surg ; 407(8): 3819-3831, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-36136152

RESUMO

PURPOSE: Extended resections in hepatopancreatobiliary (HPB) surgery frequently require vascular resection to obtain tumor clearance. The use of alloplastic grafts may increase postoperative morbidity due to septic or thrombotic complications. The use of suitable autologous venous interponates (internal jugular vein, great saphenous vein) is frequently associated with additional incisions. The aim of this study was to report on our experience with venous reconstruction using the introperative easily available parietal peritoneum, focusing on key technical aspects. METHODS: All patients who underwent HPB resections with venous reconstruction using peritoneal patches at our department between January 2017 and November 2021 were included in this retrospective analysis with median follow-up of 2 months (IQR: 1-8 months). We focused on technical aspects of the procedure and evaluated vascular patency and perioperative morbidity. RESULTS: Parietal peritoneum patches (PPPs) were applied for reconstruction of the inferior vena cava (IVC) (13 patients) and portal vein (PV) (4 patients) during major hepatic (n = 14) or pancreatic (n = 2) resections. There were no cases of postoperative bleeding due to anastomotic leakage. Following PV reconstruction, two patients showed postoperative vascular stenosis after severe pancreatitis with postoperative pancreatic fistula and bile leakage, respectively. In patients with reconstruction of the IVC, no relevant perioperative vascular complications occurred. CONCLUSIONS: The use of a peritoneal patch for reconstruction of the IVC in HPB surgery is a feasible, effective, and low-cost alternative to alloplastic, xenogenous, or venous grafts. The graft can be easily harvested and tailored to the required size. More evidence is still needed to confirm the safety of this procedure for the portal vein regarding long-term results.


Assuntos
Veia Porta , Veia Cava Inferior , Humanos , Veia Porta/cirurgia , Veia Porta/patologia , Veia Cava Inferior/cirurgia , Veia Cava Inferior/patologia , Peritônio/cirurgia , Estudos Retrospectivos , Grau de Desobstrução Vascular , Complicações Pós-Operatórias/patologia
2.
Med Oncol ; 32(7): 204, 2015 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-26071123

RESUMO

In the last years, the impact of weight loss in patients with malignant tumors has come more and more into the focus of clinical research, as the occurrence of weight loss is often associated with a reduced survival. Weight loss can be a hint for metastases in patients suffering from malignant tumors; furthermore, these patients are usually not able to be treated with chemotherapy. The aim of the study was to show the influence of weight loss and an elevated nutrition risk score on survival following tumor resection in patients suffering from gastric cancer. In 99 patients in whom a gastrectomy due to gastric cancer was performed, the nutrition risk score was calculated and its influence on mortality, morbidity and survival was analyzed. Of the included patients, 45 % of the patients gave a history of weight loss; they had significantly more often a NRS ≥ 3. In UICC stage 1a/b, a NRS ≥ 3 was associated with a significantly reduced survival compared to patients with a NRS < 3. In early tumor stages (UICC 1a/b), a NRS ≥ 3 was associated with a significantly reduced survival, while in progressed tumor stage, the influence of a poor NRS was not significant. This seems to show that in progressed stages in patients with gastric cancer, the influence of a reduced NRS is negligible.


Assuntos
Gastrectomia/efeitos adversos , Estado Nutricional/fisiologia , Neoplasias Gástricas/mortalidade , Neoplasias Gástricas/patologia , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias/métodos , Fatores de Risco , Neoplasias Gástricas/cirurgia , Redução de Peso/fisiologia
3.
Scand J Surg ; 104(3): 176-84, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-25231956

RESUMO

BACKGROUND AND AIMS: In spite of huge developments in liver surgery during the last decades, morbidity and mortality continue to pose problems in this field. The aim of this study was to identify preoperative predictors for postoperative mortality and morbidity in liver surgery. MATERIAL AND METHODS: In a single-center study, an extensive analysis of a prospective database, including clinical criteria and laboratory tests of patients undergoing liver surgery between July 2007 and July 2012 was performed. Cutoff values of selected laboratory tests were calculated. RESULTS: In all, 337 patients were included in the study. Univariate analysis showed a statistically significant association of preoperative bilirubin, lactate, hemoglobin levels, platelet count, and prothrombin time with postoperative morbidity and mortality. Multivariate analysis revealed preoperatively elevated serum bilirubin and lactate levels as independent predictors for increased postoperative morbidity and mortality after liver surgery. CONCLUSIONS: The identified laboratory values showed a statistically significant association with postoperative morbidity and mortality in liver surgery and might be helpful in preoperative patient selection.


Assuntos
Bilirrubina/sangue , Hepatectomia/efeitos adversos , Ácido Láctico/sangue , Hepatopatias/sangue , Hepatopatias/mortalidade , Adulto , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Feminino , Hepatectomia/mortalidade , Humanos , Hepatopatias/cirurgia , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Resultado do Tratamento , Adulto Jovem
4.
Transpl Infect Dis ; 15(4): E129-33, 2013 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-23790000

RESUMO

Cytomegalovirus (CMV) can cause severe infections with serious consequences in renal transplant recipients. Disseminated CMV infections can affect almost every organ, but obstructive cholestasis and cholangitis, as a consequence of a CMV-induced papillitis, is extremely rare. We are reporting a rare case of obstructive cholestasis and cholecystitis due to CMV-related inflammation of the major duodenal papilla in a 60-year-old woman 3 months after renal transplantation. In addition, the patient suffered from a disseminated CMV infection with ulcerative esophagitis and gastritis. Because of the severe CMV infection, failure of the renal graft occurred. Obstructive cholestasis was resolved through internal stenting, and the progressive cholecystitis necessitated an emergency cholecystectomy. Following antiviral therapy with ganciclovir, the gastrointestinal ulcerations regressed and renal function was restored. Diagnosis of the CMV-related disease was established only in tissue samples, whereas standard serologic tests had failed.


Assuntos
Colecistite Acalculosa , Ampola Hepatopancreática/virologia , Colangite , Colestase Intra-Hepática , Doenças do Ducto Colédoco , Infecções por Citomegalovirus , Transplante de Rim/efeitos adversos , Colecistite Acalculosa/complicações , Colecistite Acalculosa/virologia , Aloenxertos , Colangite/complicações , Colangite/virologia , Colestase Intra-Hepática/complicações , Colestase Intra-Hepática/virologia , Doenças do Ducto Colédoco/complicações , Doenças do Ducto Colédoco/virologia , Citomegalovirus/isolamento & purificação , Infecções por Citomegalovirus/complicações , Infecções por Citomegalovirus/virologia , Feminino , Humanos , Pessoa de Meia-Idade
5.
Anaesthesist ; 60(12): 1095-108, 2011 Dec.
Artigo em Alemão | MEDLINE | ID: mdl-22179072

RESUMO

Surgical replacement of aortic valves is the gold standard for therapy of high grade aortic valve stenosis. However, the changes in demography confront the responsible medical discipline with an increasingly higher risk profile of patients which necessitates the development of new less invasive alternative forms of treatment for the surgical therapy of aortic valve stenosis. This developmental process has progressed from mini-thoracotomy to transcatheter aortic valve implantation (TAVI). The TAVI procedure is a new therapeutic option for treatment of patients with high grade aortic valve stenosis and high perioperative morbidity and mortality risks with conventional aortic valve replacement. Because TAVI can be carried out while the heart is still beating and without a sternotomy or heart-lung maschine, this procedure is particularly suitable for elderly multimorbid patients and/or patients with previous cardiac surgery. The initial results of large prospective multicenter studies underline the value of TAVI in the modern treatment of high risk patients with symptomatic aortic valve stenosis. In addition to an understanding of the surgical procedure, anesthetists must have precise knowledge of the perioperative anesthesia management and possible complications of the procedure.


Assuntos
Anestesia , Valva Aórtica/cirurgia , Cateterismo Cardíaco , Cateterismo/métodos , Implante de Prótese de Valva Cardíaca/métodos , Anticoagulantes/uso terapêutico , Estenose da Valva Aórtica/cirurgia , Ecocardiografia Transesofagiana , Próteses Valvulares Cardíacas , Hemodinâmica/fisiologia , Humanos , Monitorização Intraoperatória , Estudos Multicêntricos como Assunto , Complicações Pós-Operatórias/prevenção & controle , Complicações Pós-Operatórias/terapia , Estudos Prospectivos , Desenho de Prótese , Medição de Risco , Toracotomia
7.
Int J Infect Dis ; 14(6): e528-30, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-19729330

RESUMO

We report the case of a 31-year-old immunosuppressed, liver transplanted man, with acute measles infection. The vaccinated patient had been exposed to measles during a known measles epidemic in public schools in Austria between January and April 2008. Measles infection triggered an episode of acute liver transplant rejection. The diagnosis of measles infection was made clinically and by serologic tests. Transplant rejection was diagnosed by liver biopsy. The transplant rejection was treated successfully. Liver transplant patients are at an increased risk for infection during epidemic outbreaks, even after pre-transplant vaccination, as immunity may wane over time.


Assuntos
Rejeição de Enxerto/etiologia , Sarampo/complicações , Doença Aguda , Adulto , Áustria/epidemiologia , Surtos de Doenças , Inibidores Enzimáticos/uso terapêutico , Glucocorticoides/uso terapêutico , Rejeição de Enxerto/tratamento farmacológico , Humanos , Hospedeiro Imunocomprometido , Imunossupressores/uso terapêutico , Transplante de Fígado , Masculino , Sarampo/epidemiologia , Metilprednisolona/uso terapêutico , Ácido Micofenólico/uso terapêutico , Fatores de Risco , Tacrolimo/uso terapêutico
8.
Clin Transplant ; 23 Suppl 21: 37-41, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19930315

RESUMO

Acute liver failure is a life threatening disease mostly triggered by drug-induced or toxic liver damage or viral hepatitis. Herpes Simplex virus (HSV) hepatitis is rare and accounts for only 1% of all acute liver failures. The importance of HSV-induced acute liver failure is based on its extremely severe clinical course with lethality rates of almost 75%. HSV hepatitis is just one of several clinical manifestations of HSV sepsis leading more frequently to encephalitis, pneumonia and esophagitis. Local herpes infection or recurrence of dermal lesions (herpes labialis, herpes genitalis), however, is common and account for the high prevalence of HSV-1 or HSV-2 infection in adults. Another rare entity is visual dissemination, which mostly affects immunocompromised patients. Compromised cellular immunity is a major risk factor for HSV sepsis because of either primary infection or reactivation of occult chronic HSV infection. Delayed diagnosis without antiviral therapy significantly contributes to the unfavorable outcome. Typically, anicteric hepatitis is seen in patients with HSV hepatitis. Because of its low incidence, however, and the lack of dermal manifestations, HSV hepatitis is rarely considered in the context of acute liver failure. In addition, diagnostic tests might not always be available. Therefore, it is a generally accepted consensus to begin antiviral therapy pre-emptively with acyclovir in cases of acute liver failure of unknown origin, in which high urgency (HU) liver transplantation remains the only therapeutical option. Even in the case of early specific therapy, sepsis may prevail and the indication for HU transplantation must be evaluated carefully. The outcome after liver transplantation for HSV-induced liver failure with reported survival rates of more than 40% is good. Because of the risk of recurrence, lifelong prophylaxis with acyclovir is recommended.


Assuntos
Herpes Simples/complicações , Falência Hepática Aguda/virologia , Sepse/virologia , Aciclovir/uso terapêutico , Antivirais/uso terapêutico , Herpes Simples/diagnóstico , Herpes Simples/tratamento farmacológico , Humanos , Reação em Cadeia da Polimerase
9.
Nephrol Dial Transplant ; 22 Suppl 8: viii54-viii60, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17890265

RESUMO

Since the beginning of organ transplantation, graft preservation has been one of the most important concerns. Ischemia reperfusion injury (IRI), which plays an important role in the quality and function of the graft, is a major cause for increased length of hospitalization and decreased long term graft survival. Among numerous attempts which have been made to minimize graft damage associated with IRI, the use of Thymoglobulin (TG) seems to offer potential benefits. TG is a polyclonal antibody which blocks multiple antigens related to IRI, in addition to its better known T cell depleting effects. This review will focus on the use of TG in preventing IRI in kidney transplantation (KTx) and liver transplantation (LTx). Different studies in experimental and clinical transplantation have shown that TG protects renal and liver grafts from IRI. Improvement in early graft function and decreased delayed graft function (DGF) rates are some of the clinical benefits of TG. Additionally, it is used in patients with hepatorenal syndrome to support the recovery of kidney function after LTx, by allowing reduced exposure to nephrotoxic calcineurin inhibitors as well as improving liver graft function by minimizing IRI. TG can reduce acute rejection rates in kidney and liver transplant recipients, decrease the length of hospital stay, and hence reduce transplantation costs. TG can play an important role in expanding the donor pool in both KTx and LTx by improving long-term graft and patient survival rates which increases the possibility of using marginal donors. Although controversial, the development of post-transplant lymphoproliferative disorder is a potential side effect of TG. No single optimal immunosuppressive regimen has given consistent results in decreasing the graft damage following IRI; however, TG usage in KTx and LTx appears to have some benefits in reducing IRI.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Transplante de Rim/métodos , Transplante de Fígado/métodos , Traumatismo por Reperfusão/terapia , Anticorpos Monoclonais/química , Soro Antilinfocitário , Ensaios Clínicos como Assunto , Rejeição de Enxerto , Sobrevivência de Enxerto , Humanos , Imunossupressores/uso terapêutico , Transplante Homólogo , Resultado do Tratamento
10.
Helicobacter ; 4(2): 113-20, 1999 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-10382125

RESUMO

BACKGROUND: Due to its unique pharmacokinetic properties, azithromycin may be an attractive combination partner for H. pylori eradication regimens. However, up to 15% of clinical isolates are primarily resistant to azithromycin as well as to other macrolide antibiotics. Combination therapy with lansoprazole, a proton pump inhibitor known to have intrinsic antibacterial activity against H. pylori, may be useful to counteract such resistance. We therefore evaluated the combined effects of azithromycin and lansoprazole in vitro. MATERIALS AND METHODS: Minimal inhibitory concentrations (MICs) of azithromycin and lansoprazole alone and in combination were determined for 106 clinical H. pylori isolates by means of an agar dilution technique. Killing kinetics of seven isolates were also studied in fluid medium. RESULTS: MIC values for 50 and 90% of the isolates (MIC50, MIC90) were 0.19 and 0.5 mg/l for azithromycin, and 44.5 and 104 mg/l for lansoprazole. Nine strains (8.5%) had an MIC of azithromycin > or = 16 mg/l and were regarded as resistant. An additive interaction between the two drugs was found in 72 (68%), and indifferent effects in 24 strains (23%). Three of 9 azithromycin-resistant strains regained sensitivity in the presence of lansoprazole. In fluid culture, synergism between the two drugs occurred in 6 out of 7 strains tested. CONCLUSION: In the majority of strains, lansoprazole and azithromycin interacted in an additive or synergistic manner depending on the test method employed. Addition of lansoprazole restored in vitro sensitivity to azithromycin in 3 out of 9 azithromycin-resistant strains. Such effects may enhance the elimination of H. pylori during clinical eradication therapy.


Assuntos
Azitromicina/farmacologia , Infecções por Helicobacter/microbiologia , Helicobacter pylori/efeitos dos fármacos , Omeprazol/análogos & derivados , 2-Piridinilmetilsulfinilbenzimidazóis , Antibacterianos/farmacologia , Sinergismo Farmacológico , Humanos , Lansoprazol , Testes de Sensibilidade Microbiana , Omeprazol/farmacologia , Inibidores da Bomba de Prótons
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...